Subtopic Deep Dive

Connexins in Ocular Diseases
Research Guide

What is Connexins in Ocular Diseases?

Connexins in ocular diseases refers to the role of connexin mutations, particularly Cx50 in congenital cataracts and Cx43 in oculodentodigital dysplasia, disrupting gap junction communication in eye tissues leading to blinding conditions.

Mutations in GJA1 (Cx43) cause oculodentodigital dysplasia with eye abnormalities (Paznekas et al., 2009, 257 citations). Cx50 mutations link to congenital cataracts through lens fiber cell dysfunction (Francis et al., 2000, 193 citations). Over 20 papers document connexin hemichannel dysregulation in retinopathies and cataracts.

Curated Papers

Key Challenges

Why It Matters

Cx43 dysfunction in GJA1 mutations drives oculodentodigital dysplasia phenotypes including cataracts and microphthalmia, affecting vision in affected families (Paznekas et al., 2009). Cx50 genetic defects cause childhood cataracts, impacting 1 in 10,000 births and spurring gene therapy trials (Francis et al., 2000). Gap junction failures exacerbate inflammation in ocular barriers, as connexins interact with tight junctions (Förster, 2008). Therapeutic modulation targets hemichannels to prevent lens opacification and retinopathy progression.

Key Research Challenges

Cx43 Trafficking Defects

GJA1 mutations impair connexin43 trafficking to plasma membranes, disrupting gap junctions in ocular cells (Paznekas et al., 2009). This leads to variable penetrance in oculodentodigital dysplasia eye phenotypes. Rescue strategies face challenges in mutant protein stability.

Lens Cx50 Mutation Effects

Cx50 mutations cause congenital cataracts by altering lens fiber intercellular communication (Francis et al., 2000). Phenotypic heterogeneity complicates diagnosis. Hemichannel hyperactivity promotes cell death in lens epithelium.

Hemichannel Dysregulation

Connexin hemichannels in ocular tissues release ATP, fueling inflammation in retinopathies (Goodenough and Paul, 2009). Disease models struggle to isolate hemichannel vs. gap junction roles. Pharmacological blockers lack specificity for eye applications.

Essential Papers

Tight junctions and the modulation of barrier function in disease

Carola Y. Förster · 2008 · Histochemistry and Cell Biology · 585 citations

Tight junctions create a paracellular barrier in epithelial and endothelial cells protecting them from the external environment. Two different classes of integral membrane proteins constitute the t...

Gap Junctions

D A Goodenough, D. L. Paul · 2009 · Cold Spring Harbor Perspectives in Biology · 580 citations

Gap junctions are aggregates of intercellular channels that permit direct cell-cell transfer of ions and small molecules. Initially described as low-resistance ion pathways joining excitable cells ...

Cell-cell communication in carcinogenesis

James E. Trosko · 1998 · Frontiers in bioscience · 512 citations

To explain the complex carcinogenic process by which a single normal cell in human beings can be converted to an invasive and metastatic cancer cell, a number of experimental findings, epidemiologi...

<i>GJA1</i>mutations, variants, and connexin 43 dysfunction as it relates to the oculodentodigital dysplasia phenotype

William A. Paznekas, Barbara Karczeski, Sascha Vermeer et al. · 2009 · Human Mutation · 257 citations

The predominantly autosomal dominant disorder, oculodentodigital dysplasia (ODDD) has high penetrance with intra- and interfamilial phenotypic variability. Abnormalities observed in ODDD affect the...

Connexin29 Is Uniquely Distributed within Myelinating Glial Cells of the Central and Peripheral Nervous Systems

Bruce M. Altevogt, Kleopas A. Kleopa, Friso R. Postma et al. · 2002 · Journal of Neuroscience · 254 citations

Although both Schwann cells and oligodendrocytes express connexin32 (Cx32), the loss of this connexin causes demyelination only in the PNS. To determine whether oligodendrocytes might express anoth...

Connexins in Cardiovascular and Neurovascular Health and Disease: Pharmacological Implications

Luc Leybaert, Paul D. Lampe, Stefan Dhein et al. · 2017 · Pharmacological Reviews · 244 citations

A deletion mutation in GJB6 cooperating with a GJB2 mutation in trans in non-syndromic deafness: A novel founder mutation in Ashkenazi Jews

Israela Lerer, Michal Sagi, Ziva Ben‐Neriah et al. · 2001 · Human Mutation · 220 citations

A deletion of at least 140 kb starting approximately 35kb upstream (telomeric) to the GJB2 (CX26) gene was identified in 7 patients from 4 unrelated Jewish Ashkenazi families with non-syndromic hea...

Reading Guide

Foundational Papers

Read Goodenough and Paul (2009, 580 citations) first for gap junction fundamentals in tissues; then Paznekas et al. (2009, 257 citations) for Cx43 ocular mutations; Francis et al. (2000, 193 citations) for lens connexin genetics.

Recent Advances

Leybaert et al. (2017, 244 citations) covers connexin pharmacology in neurovascular disease including eyes; Taruno (2018, 194 citations) details ATP hemichannel release relevant to ocular inflammation.

Core Methods

Core methods: genetic mutation screening (Paznekas et al., 2009), pedigree analysis (Francis et al., 2000), dye-coupling assays for junctions (Goodenough and Paul, 2009), and barrier permeability tests (Förster, 2008).

How PapersFlow Helps You Research Connexins in Ocular Diseases

Discover & Search

Research Agent uses searchPapers('Cx50 congenital cataracts') to retrieve Francis et al. (2000), then citationGraph to map 193+ citing works on lens connexins, and findSimilarPapers to uncover related GJA8 mutations. exaSearch('Cx43 oculodentodigital dysplasia eye') surfaces Paznekas et al. (2009) and variants.

Analyze & Verify

Analysis Agent applies readPaperContent on Paznekas et al. (2009) to extract GJA1 mutation spectra, verifies claims with CoVe against Goodenough and Paul (2009), and runs PythonAnalysis to quantify mutation penetrance from pedigree data using pandas. GRADE grading scores evidence as high for Cx43-ODDD links.

Synthesize & Write

Synthesis Agent detects gaps in Cx50 therapy papers via contradiction flagging, then Writing Agent uses latexEditText for manuscript sections, latexSyncCitations for 10+ refs, and latexCompile for PDF. exportMermaid generates signaling diagrams of hemichannel ATP release in cataracts.

Use Cases

"Analyze mutation frequencies in Cx50 cataracts from genetic datasets"

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis(pandas frequency count on Francis et al. 2000 pedigrees) → CSV export of prevalence stats.

"Draft review section on Cx43 in ODDD with citations and figure"

Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations(Paznekas 2009) + latexGenerateFigure(ODDD eye phenotype) → latexCompile PDF.

"Find code for connexin hemichannel simulations in ocular models"

Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python sandbox test of simulation scripts.

Automated Workflows

Deep Research workflow scans 50+ connexin papers via searchPapers → citationGraph, producing structured report on Cx50/Cx43 in cataracts with GRADE scores. DeepScan applies 7-step CoVe to verify hemichannel claims in Paznekas et al. (2009). Theorizer generates hypotheses on Cx43-tight junction interactions from Förster (2008) and Goodenough (2009).

Try Doxa for Connexins in Ocular Diseases Research

Frequently Asked Questions

What defines connexins in ocular diseases?

Connexins in ocular diseases involve Cx50 mutations causing congenital cataracts and Cx43 (GJA1) defects leading to oculodentodigital dysplasia eye phenotypes (Francis et al., 2000; Paznekas et al., 2009).

What methods study connexin dysfunction in eyes?

Methods include genetic sequencing of GJA1/Cx50 mutations, immunofluorescence for gap junction plaques, and hemichannel assays measuring ATP release (Paznekas et al., 2009; Goodenough and Paul, 2009).

What are key papers on this topic?

Paznekas et al. (2009, 257 citations) details GJA1 mutations in ODDD; Francis et al. (2000, 193 citations) maps Cx50 to cataracts; Goodenough and Paul (2009, 580 citations) reviews gap junction basics.

What open problems exist?

Challenges include specific hemichannel blockers for ocular use, variable penetrance mechanisms in Cx43 mutants, and gene therapies rescuing lens Cx50 traffic (Paznekas et al., 2009; Francis et al., 2000).